Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

Advances in Biological Augmentation for Muscle and Tendon Repair: Regenerative and Reconstructive Approaches in Elite Sports Medicine

Abraham Saynes Jarquin
UNAM
abrahamsaynes02@gmail.com
https://orcid.org/0009-0006-2983-8634

Cristian Israel Sarmiento Bonilla
UMAE "Dr. Victorio De La Fuente Narváez"
cristian_i_sarmiento@outlook.com
https://orcid.org/0009-0009-3799-2625

Steeven Alexander Pinzón Narváez
NOVACONS SAS
pinzonsteven0@gmail.com
https://orcid.org/0009-0003-7806-6122

Joaury Luis Arteaga Teran
Universidad de Guayaquil
joauryteranec@hotmail.com
https://orcid.org/0009-0000-2772-6328

Fabián Patricio Miranda Yáñez
Universidad San Sebastián
mirandayanezfabian@gmail.com
https://orcid.org/0009-0008-7065-2887

André Ayala Rodríguez
Universidad Anáhuac México
ayalaandree30@gmail.com
https://orcid.org/0009-0009-3724-1645

Stephanie Paola Feijóo Tapia
Universidad de Guayaquil
sfeijoo4@gmail.com
https://orcid.org/0009-0008-3423-9411

Alexa Fernanda Uriostegui Navarro
Universidad del Valle de Cuernavaca
fernavarro0401@gmail.com
https://orcid.org/0009-0007-9161-3177

Received: 29-Jul-2026 | **Accepted:** 29-Jul-2026 | **Published:** 31-Jul-2026

*** Corresponding Author:** abrahamsaynes02@gmail.com

How to cite this article: Saynes Jarquin, A., Pinzón Narváez, S. A., Miranda Yáñez, F. P., Feijóo Tapia, S. P., Sarmiento Bonilla, C. I., Arteaga Teran, J. L., Ayala Rodríguez, A., & Uriostegui Navarro, A. F. (2026). Advances in Biological Augmentation for Muscle and Tendon Repair: Regenerative and Reconstructive Approaches in Elite Sports Medicine. México. *International Science Journal* "TheSci". 4 (1) 168-190. Quality Consulting Instituto de Educación Capacitación y Certificación de México. https://ieccmexico.com/thesci

ABSTRACT

Muscle and tendon injuries remain among the most common causes of functional impairment and time-loss in elite athletes, representing a significant challenge for reconstructive surgery, sports medicine, and rehabilitation. Conventional treatment approaches frequently restore anatomical continuity but may not completely reproduce the biological and biomechanical properties of healthy tissue, increasing the risk of delayed recovery and recurrent injury. In recent years, biological augmentation has emerged as a promising strategy to enhance tissue regeneration

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

through modulation of inflammation, stimulation of angiogenesis, promotion of extracellular matrix remodeling, and improvement of collagen organization. This narrative review critically examined current scientific evidence regarding the biological basis, clinical applications, and therapeutic potential of platelet-rich plasma, bone marrow aspirate concentrate, mesenchymal stromal cells, extracellular vesicles, exosomes, biomaterials, and tissue-engineered constructs for the management of muscle and tendon injuries in elite athletes. Current evidence suggests that platelet-rich plasma remains the most extensively investigated biological intervention, whereas cell-based therapies, biomaterials, and exosome-derived approaches continue to demonstrate considerable regenerative potential despite requiring further clinical validation. The findings also emphasize that successful recovery depends not only on biological augmentation but also on accurate diagnosis, individualized patient selection, technically sound reconstructive procedures, structured rehabilitation, progressive mechanical loading, and multidisciplinary clinical management. Although regenerative medicine continues to evolve rapidly, methodological heterogeneity among available studies highlights the need for standardized treatment protocols and large multicenter clinical investigations. Overall, biological augmentation represents a valuable adjunct to contemporary reconstructive strategies, offering new opportunities to improve tissue healing, functional recovery, and safe return to competitive sport in elite athletes.

KEYWORDS

Biological augmentation, Muscle injury, Tendon injury, Regenerative medicine, Platelet-rich plasma, Mesenchymal stromal cells, Bone marrow aspirate concentrate, Exosomes, Biomaterials, Tissue engineering, Reconstructive surgery, Sports medicine, Rehabilitation, Return to play, Elite athletes.

INTRODUCTION

Muscle and tendon injuries remain among the most prevalent and clinically challenging conditions affecting elite athletes across professional and Olympic sports. These injuries account for a substantial proportion of time-loss events, reduced athletic performance, and premature career termination, particularly in sports characterized by repetitive high-intensity movements, explosive acceleration, rapid deceleration, and multidirectional loading [1], [7], [10]. Despite significant advances in surgical reconstruction, rehabilitation science, and sports medicine over the past two decades, recurrence rates following severe musculotendinous injuries remain unacceptably high, with recurrent lesions often demonstrating prolonged recovery periods, inferior biomechanical properties, and increased susceptibility to chronic degeneration [6], [9]. Consequently, optimizing biological healing rather than merely restoring structural continuity has become one of the principal objectives of contemporary reconstructive strategies.

The biological complexity of skeletal muscle and tendon repair explains many of the current therapeutic challenges. Following injury, healing progresses through highly coordinated inflammatory, proliferative, angiogenic, and remodeling phases involving immune cells, fibroblasts, satellite cells, extracellular matrix components, growth factors, and mechanical signaling pathways [1], [8]. Although this cascade is capable of restoring tissue continuity, regenerative capacity is frequently limited by excessive fibrosis, disorganized collagen deposition, impaired vascularization, and incomplete functional restoration. In elite athletes, where even minimal biomechanical deficits may compromise competitive performance, conventional treatment strategies often fail to reproduce the structural and mechanical characteristics of native tissue [8], [17]. These biological limitations have encouraged the development of regenerative approaches designed to enhance endogenous healing mechanisms while minimizing scar formation and facilitating earlier return to sport.

Over the past decade, biological augmentation has emerged as one of the fastest-growing fields in sports medicine and reconstructive surgery. Rather than replacing damaged tissues, biological augmentation seeks to optimize the intrinsic healing environment through the administration of autologous or biologically active products capable of modulating inflammation, stimulating angiogenesis, promoting cellular proliferation, and improving extracellular matrix organization [1], [14]. Current strategies encompass platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), mesenchymal stromal cells, adipose-derived stem cells, extracellular vesicles, exosomes, collagen-based scaffolds, bioengineered matrices, hydrogels, and tissue-engineered constructs. Many of these interventions are

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

increasingly incorporated into multidisciplinary treatment protocols involving orthopedic surgeons, plastic and reconstructive surgeons, sports physicians, rehabilitation specialists, physiotherapists, and biomedical engineers [2], [3], [16].

Among these therapies, platelet-rich plasma remains the most extensively investigated biological intervention. PRP contains supraphysiological concentrations of platelets that release numerous bioactive molecules, including platelet-derived growth factor, transforming growth factor-β, vascular endothelial growth factor, insulin-like growth factor-1, fibroblast growth factor, and epidermal growth factor, all of which contribute to cellular migration, angiogenesis, collagen synthesis, and tissue remodeling [1], [4]. Nevertheless, despite widespread clinical adoption, published evidence continues to demonstrate heterogeneous outcomes attributable to variability in preparation protocols, platelet concentration, leukocyte content, injection timing, rehabilitation protocols, injury severity, and outcome assessment methods [4], [5]. Consequently, recent consensus statements emphasize the necessity for standardized protocols before definitive recommendations can be universally established.

Simultaneously, advances in regenerative medicine have expanded therapeutic possibilities beyond platelet-derived products. Mesenchymal stromal cells obtained from bone marrow or adipose tissue possess immunomodulatory, anti-inflammatory, and trophic properties capable of influencing multiple phases of tissue repair through paracrine signaling rather than direct cellular replacement [2], [16]. Experimental studies have demonstrated enhanced collagen organization, improved vascularization, reduced fibrosis, and superior biomechanical strength following cell-based interventions in both muscle and tendon models. Likewise, extracellular vesicles and exosomes have attracted increasing scientific attention because they may reproduce many regenerative effects of stem cells while avoiding several regulatory, ethical, and safety concerns associated with cellular transplantation [2], [3]. These nanoscale vesicles transport proteins, lipids, messenger RNA, and microRNA that regulate intercellular communication and influence inflammation, angiogenesis, matrix remodeling, and tissue regeneration.

Parallel progress has also occurred in biomaterials and tissue engineering. Biological scaffolds, decellularized extracellular matrices, collagen membranes, synthetic polymers, injectable hydrogels, and bioactive implants are being developed to provide mechanical support while simultaneously serving as biological platforms that facilitate cell migration, vascular ingrowth, and matrix deposition [9], [14], [17]. Recent advances in three-dimensional bioprinting and biofabrication further suggest the possibility of producing patient-specific constructs capable of restoring complex musculotendinous architecture, thereby opening new perspectives for reconstructive surgery in athletes with extensive tissue loss or recurrent injuries.

Plastic and reconstructive surgery has progressively adopted these regenerative principles to complement conventional surgical repair. Biological augmentation is increasingly employed during tendon reconstruction, rotator cuff repair, Achilles tendon reconstruction, patellar tendon repair, chronic muscle rupture management, and soft tissue reconstruction following sports-related trauma [14], [17]. Instead of relying exclusively on mechanical fixation, modern reconstructive procedures increasingly integrate biological adjuncts intended to improve graft incorporation, reduce inflammatory responses, accelerate tissue maturation, and decrease failure rates. Such strategies are particularly relevant for elite athletes, where minimizing recovery time while preserving long-term tissue integrity remains a fundamental therapeutic priority.

Despite these promising developments, important uncertainties remain regarding clinical efficacy, optimal patient selection, treatment timing, dosing protocols, long-term safety, cost-effectiveness, and regulatory oversight. Considerable heterogeneity persists across published clinical trials, with substantial differences in injury classification, rehabilitation protocols, biological product preparation, imaging follow-up, functional outcome measures, and return-to-play criteria [5], [6], [10]. These methodological inconsistencies limit direct comparison among studies and complicate evidence-based decision-making for clinicians responsible for managing high-performance athletes. Furthermore, the rapid commercialization of regenerative therapies has frequently outpaced the generation of high-quality clinical evidence, highlighting the importance of critically evaluating current scientific knowledge before widespread implementation.

The growing international interest in biological augmentation extends beyond North America and Europe. Increasing contributions from research groups in Latin America, Asia, and Oceania have broadened understanding of regenerative

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

therapies within diverse healthcare systems, expanding collaborative multicenter research and facilitating the adaptation of biological treatments to different clinical environments. Several Latin American sports medicine centers have progressively incorporated ultrasound-guided biologic interventions, multidisciplinary rehabilitation protocols, and individualized return-to-play strategies, contributing valuable clinical experience that complements evidence generated by large international institutions. This global expansion reinforces the need for comprehensive evidence synthesis capable of integrating findings from multiple geographical regions while identifying common principles applicable across different healthcare settings.

Given the rapid evolution of regenerative technologies, continuous emergence of novel biologics, and increasing demand for accelerated recovery among elite athletes, an updated synthesis of current evidence is both timely and clinically relevant. Understanding the biological mechanisms underlying tissue regeneration, the indications for various augmentation strategies, and their integration within modern reconstructive surgery and rehabilitation protocols may contribute to more individualized therapeutic decision-making and improved functional outcomes.

Accordingly, the objective of this narrative review is to critically examine the contemporary evidence regarding biological augmentation strategies for muscle and tendon injuries in elite athletes. Specifically, this review analyzes the biological basis of tissue repair, current regenerative therapies, reconstructive surgical applications, advances in tissue engineering, rehabilitation strategies, return-to-play considerations, emerging technologies, and future directions in precision sports medicine. By integrating current experimental and clinical evidence from multiple disciplines, this article aims to provide healthcare professionals, researchers, and sports medicine specialists with a comprehensive overview of the evolving role of biological augmentation in optimizing musculoskeletal healing and athletic recovery.

DEVELOPMENT

Muscle and tendon injuries in elite athletes represent a complex clinical problem because their consequences extend beyond tissue damage. They may alter biomechanical efficiency, reduce competitive performance, increase the probability of reinjury, and interrupt an athlete's career. Unlike recreationally active individuals, professional athletes are frequently expected to recover within restricted competitive schedules and return to training at levels approaching their preinjury capacity. Consequently, successful treatment should not be limited to pain reduction or anatomical continuity; it should also restore tissue strength, elasticity, neuromuscular control, and tolerance to sport-specific loading.

Skeletal muscle and tendon differ considerably in their structure, vascular supply, cellular composition, and regenerative capacity. Muscle healing is supported by satellite cells capable of proliferating and differentiating after injury. However, severe or recurrent lesions may produce hematoma formation, persistent inflammation, excessive extracellular matrix deposition, and fibrotic scar tissue. Fibrosis restores continuity but does not reproduce the contractile properties of healthy muscle, potentially creating a mechanically vulnerable region with reduced extensibility [8]. Tendons present an additional challenge because of their relatively limited vascularity, low cellular density, and slow extracellular matrix turnover. During tendon repair, the initial collagen network is frequently disorganized and dominated by type III collagen, which provides less tensile strength than the type I collagen characteristic of mature tendon tissue [6], [17].

These characteristics explain why conventional management does not always produce complete biological restoration. Early care generally includes protection of the injured structure, symptom control, progressive mobilization, and rehabilitation based on gradual mechanical loading. Surgical repair may be required for complete ruptures, major retractions, chronic defects, loss of functional continuity, or failure of conservative treatment. Nevertheless, surgery primarily restores mechanical approximation. It does not necessarily correct the altered biological environment responsible for delayed healing, adhesions, poor graft incorporation, fibrosis, or recurrent rupture [14]. Biological augmentation has therefore been proposed as a complementary strategy rather than a replacement for appropriate diagnosis, surgical technique, and rehabilitation.

Biological augmentation includes the application of cellular, molecular, or biomaterial-based interventions intended to improve one or more phases of tissue repair. Its principal targets include regulation of the inflammatory response,

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

stimulation of angiogenesis, recruitment of reparative cells, enhancement of collagen synthesis, organization of the extracellular matrix, and improvement of the mechanical properties of the repaired tissue. Platelet-rich plasma, bone marrow aspirate concentrate, mesenchymal stromal cells, adipose-derived cellular preparations, extracellular vesicles, exosomes, collagen scaffolds, decellularized matrices, and bioactive hydrogels constitute the principal strategies currently under investigation.

Platelet-rich plasma is the most widely used biological intervention in sports medicine. Once activated, platelets release growth factors and signaling proteins involved in chemotaxis, cell proliferation, vascular formation, matrix synthesis, and tissue remodeling [1]. PRP is attractive because it is autologous, can be prepared relatively rapidly, and may be delivered through ultrasound-guided injection or applied during reconstructive surgery. However, PRP should not be considered a uniform therapeutic product. Its biological activity varies according to platelet concentration, leukocyte content, activation method, centrifugation protocol, injected volume, timing of administration, and characteristics of the injured tissue.

This lack of standardization partly explains the inconsistent clinical findings reported across muscle and tendon injuries. In some tendinopathies, PRP has been associated with improvements in pain and function, particularly when combined with structured loading programs. Conversely, other studies have not demonstrated clear superiority over placebo, dry needling, or evidence-based rehabilitation [4], [11]. A systematic review of ultrasound-guided PRP injections also identified considerable variation across clinical protocols, supporting the need to interpret results according to the treated tendon, preparation technique, and comparator intervention. Similarly, evidence for Achilles tendinopathy remains inconclusive, despite the biological plausibility and widespread clinical use of PRP.

Cell-based treatments seek to provide or stimulate populations capable of supporting tissue regeneration. Mesenchymal stromal cells obtained from bone marrow or adipose tissue have demonstrated immunomodulatory, angiogenic, antifibrotic, and trophic activity. Their effects appear to depend largely on paracrine signaling rather than direct and permanent transformation into mature muscle or tendon cells. These cells release cytokines, growth factors, and extracellular vesicles that influence macrophage polarization, fibroblast behavior, vascular development, and extracellular matrix remodeling [16], [17]. In reconstructive procedures, cellular products may be applied around a repaired tendon, introduced into a scaffold, or combined with an autologous graft to promote biological integration.

Clinical translation, however, remains incomplete. Evidence from experimental models is generally more favorable than evidence from controlled human trials. Differences in cellular source, isolation procedures, culture conditions, viability, dose, delivery route, and regulatory classification make direct comparisons difficult. Some clinical studies have reported improved tendon healing after mesenchymal cell augmentation, including findings in rotator cuff reconstruction, but these results cannot yet be generalized to all anatomical locations or athlete populations [14]. One case-controlled study reported improved healing and fewer recurrent tears after mesenchymal stem-cell augmentation of rotator cuff repair, although its design does not provide the same level of certainty as a large randomized trial.

Extracellular vesicles and exosomes represent a developing cell-free approach. These structures transport proteins, lipids, messenger RNA, and microRNA between cells and may reproduce part of the paracrine activity attributed to mesenchymal stromal cells. Preclinical studies suggest that they may regulate inflammation, stimulate angiogenesis, improve collagen alignment, and support tendon-to-bone integration [2], [3]. A systematic review found generally positive effects of exosomes on tendon and tendon–bone healing, but also emphasized that the optimal cellular source, isolation method, concentration, administration frequency, and delivery system remain unknown [2]. Another systematic review of mesenchymal stromal cell-derived extracellular vesicles identified promising in vivo findings while confirming that available evidence remains predominantly preclinical.

Biomaterials may provide an additional solution when biological signaling alone is insufficient. Collagen membranes, decellularized extracellular matrices, synthetic polymers, fibrin matrices, and injectable hydrogels can create a temporary microenvironment that supports cellular attachment and tissue organization. In extensive muscle loss or chronic tendon defects, scaffolds may also bridge structural gaps and distribute mechanical forces while newly formed tissue develops. Their effectiveness depends on biocompatibility, degradation rate, porosity, mechanical resistance, vascular integration, and the capacity to deliver cells or growth factors in a controlled manner [14], [17].

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

The combination of biological and reconstructive strategies is particularly relevant for complex injuries. Direct repair may be adequate for acute lesions with limited tissue loss, whereas chronic ruptures may require tendon transfers, autografts, allografts, fascial reinforcement, muscle flaps, or composite reconstruction. In these situations, biological augmentation may be applied to the repair interface to enhance graft incorporation and remodeling. Plastic and reconstructive surgery contributes not only to tendon continuity but also to the restoration of vascularized soft-tissue coverage, gliding surfaces, muscle function, and anatomical contour. This multidisciplinary perspective is important in injuries involving extensive scarring, repeated surgical procedures, exposed structures, or combined muscle, tendon, nerve, and skin damage.

Rehabilitation remains the principal mechanism through which biological repair is converted into functional recovery. Mechanical loading influences tenocyte activity, collagen alignment, muscle architecture, and neuromuscular adaptation. An intervention that stimulates collagen production without an appropriate loading program may result in abundant but mechanically disorganized tissue. Conversely, excessive loading during early repair may cause elongation, microfailure, or recurrent rupture. Rehabilitation should therefore progress from protection and controlled mobility to isometric exercise, isotonic strengthening, eccentric or heavy–slow resistance training, plyometric activity, running progression, and sport-specific tasks according to the injured structure and biological stage of healing [9], [10].

Return-to-play decisions should not be based exclusively on elapsed time or symptom resolution. Athletes may become pain-free before recovering sufficient strength, rate of force development, tendon stiffness, flexibility, movement quality, or resistance to fatigue. Objective assessment should incorporate clinical examination, imaging when indicated, strength testing, functional performance, workload tolerance, psychological readiness, and sport-specific demands [10]. Biological augmentation cannot compensate for inadequate rehabilitation or premature return to competition. Its potential value lies in supporting the healing environment while progressive loading restores functional capacity.

Current evidence therefore supports a cautious and individualized interpretation of biological augmentation. PRP has the largest clinical evidence base, although its effectiveness varies by indication and preparation. Cell-based products and exosomes offer substantial regenerative potential, but their strongest evidence continues to come from laboratory and animal studies. Biomaterials and tissue-engineered constructs may be especially useful in reconstructive scenarios involving tissue loss, but many applications remain investigational. Across all approaches, heterogeneity in protocols, small samples, limited athlete-specific trials, and inconsistent return-to-play outcomes prevent universal recommendations.

International collaboration is required to overcome these limitations. Multicenter studies involving North America, Europe, Asia, Oceania, and Latin America could improve sample diversity and determine whether therapeutic outcomes remain consistent across healthcare systems and athletic populations. Latin American centers can contribute through expertise in ultrasound-guided interventions, sports rehabilitation, reconstructive surgery, and the management of athletes in settings with variable access to advanced biological technologies. Such participation is essential to prevent future recommendations from being derived exclusively from a limited number of high-income regions.

GENERAL OBJECTIVE AND SPECIFIC OBJECTIVES

To critically analyze the current scientific evidence regarding biological augmentation strategies for muscle and tendon injuries in elite athletes, integrating advances in reconstructive surgery, regenerative medicine, sports medicine, and rehabilitation in order to identify their biological foundations, clinical applications, therapeutic effectiveness, and future perspectives for optimizing tissue healing and return-to-play outcomes.

A. Cognitive Domain

1. **Identify** the biological mechanisms involved in skeletal muscle and tendon healing following acute and chronic sports-related injuries.

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

2. **Explain** the principles, indications, and mechanisms of action of contemporary biological augmentation therapies, including platelet-rich plasma, bone marrow aspirate concentrate, mesenchymal stromal cells, extracellular vesicles, exosomes, and biomaterial-based scaffolds.
3. **Analyze** the available clinical and experimental evidence supporting biological augmentation strategies in reconstructive surgery and sports medicine, emphasizing their advantages, limitations, and current controversies.
4. **Compare** conventional reconstructive approaches with biologically enhanced interventions in terms of tissue regeneration, functional recovery, complication rates, and return-to-play outcomes.

B. Psychomotor Domain

5. **Apply** current evidence to describe multidisciplinary therapeutic approaches integrating biological augmentation, reconstructive surgery, and rehabilitation for muscle and tendon injuries in elite athletes.
6. **Demonstrate** the sequential integration of biological therapies within surgical reconstruction and rehabilitation protocols according to injury characteristics and stages of tissue healing.

C. Affective Domain

7. **Recognize** the importance of evidence-based decision-making when selecting biological augmentation strategies for athletes with different clinical characteristics and performance demands.
8. **Value** multidisciplinary collaboration among reconstructive surgeons, sports physicians, rehabilitation specialists, physiotherapists, radiologists, and biomedical researchers to optimize functional recovery and minimize reinjury risk.
9. **Promote** continuous scientific evaluation of emerging regenerative technologies while encouraging responsible clinical implementation based on high-quality evidence, patient safety, and individualized therapeutic planning.

OBJECT OF STUDY

The object of this study comprises the biological augmentation strategies currently employed or under investigation for the management of muscle and tendon injuries in elite athletes, with particular emphasis on their integration into reconstructive surgery, sports medicine, and rehabilitation. The review focuses on the biological, biomechanical, and clinical processes that influence tissue regeneration following acute and chronic musculotendinous injuries, including the mechanisms through which regenerative therapies may enhance structural repair, functional recovery, and return-to-play outcomes.

The phenomenon under investigation involves the interaction between tissue healing biology and emerging regenerative interventions designed to optimize the physiological repair process. This includes the modulation of inflammation, stimulation of angiogenesis, enhancement of extracellular matrix remodeling, promotion of collagen maturation, reduction of fibrosis, and restoration of biomechanical integrity. These processes are analyzed within the context of current biological therapies, including platelet-rich plasma, bone marrow aspirate concentrate, mesenchymal stromal cells, extracellular vesicles, exosomes, bioactive scaffolds, collagen matrices, hydrogels, and tissue-engineered constructs.

The target population considered throughout this review consists primarily of elite athletes participating in professional, Olympic, collegiate, and high-performance sports who sustain muscle or tendon injuries requiring conservative management, reconstructive surgery, or multidisciplinary rehabilitation. Although much of the available

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

evidence originates from studies involving adult athletes, relevant findings from translational research, experimental animal models, and selected investigations involving physically active populations are also considered when they contribute to understanding biological mechanisms or therapeutic effectiveness.

From a clinical perspective, this review addresses injuries affecting major musculotendinous structures frequently encountered in high-performance sports, including hamstring strains, quadriceps injuries, adductor injuries, Achilles tendon ruptures, patellar tendinopathy, rotator cuff tears, pectoralis major ruptures, and other complex soft tissue injuries associated with repetitive mechanical loading or acute trauma. These conditions represent some of the leading causes of time-loss injuries, recurrent disability, and prolonged rehabilitation among elite athletes worldwide.

The study also encompasses the multidisciplinary healthcare system responsible for managing these injuries. This system involves reconstructive surgeons, orthopedic surgeons, sports medicine physicians, physiatrists, rehabilitation specialists, physiotherapists, radiologists, biomedical engineers, sports scientists, and other healthcare professionals who contribute to diagnosis, surgical treatment, biological augmentation, rehabilitation planning, functional assessment, and return-to-play decision-making.

As a narrative review, the object of study is not limited to evaluating the effectiveness of individual biological products. Instead, it seeks to examine the current body of scientific knowledge regarding regenerative strategies as complementary interventions within comprehensive treatment pathways. Particular attention is given to the biological rationale supporting these therapies, their potential indications, clinical limitations, methodological challenges, and future role in precision sports medicine.

Finally, the review considers the global evolution of biological augmentation, integrating evidence generated by research groups from North America, Europe, Asia, Oceania, and Latin America. This international perspective facilitates a broader understanding of how regenerative technologies are being incorporated into diverse healthcare systems while identifying common principles that may guide future clinical practice and multidisciplinary research.

.

METHODOLOGY

This study was conducted as a **narrative literature review** using the **Scientific Method** as the guiding methodological framework. This approach was selected because it allows the systematic identification, organization, critical interpretation, and integration of current scientific evidence concerning biological augmentation strategies for muscle and tendon injuries in elite athletes. The methodology was designed to ensure transparency, reproducibility, and consistency throughout the review process while providing a comprehensive synthesis of multidisciplinary evidence derived from sports medicine, reconstructive surgery, regenerative medicine, rehabilitation, and biomedical sciences.

The scientific method was implemented through sequential stages beginning with the identification of the research problem, followed by the formulation of the review objective, systematic literature retrieval, critical evaluation of available evidence, synthesis of findings, and generation of evidence-based conclusions. Although this review does not involve experimental intervention or statistical meta-analysis, the methodological process follows internationally accepted principles for conducting narrative scientific reviews.

Study Design

The investigation was designed as an international narrative review of published scientific literature. The review focused on current evidence regarding biological augmentation techniques applied to muscle and tendon injuries in elite athletes, emphasizing their biological mechanisms, reconstructive applications, rehabilitation strategies, and clinical outcomes. Evidence from experimental research, clinical investigations, systematic reviews, meta-analyses, consensus statements, and international clinical guidelines was integrated to provide a comprehensive overview of the topic.

Information Sources

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

Scientific publications were identified through searches performed in internationally recognized biomedical databases, including:

- PubMed/MEDLINE
- Scopus
- Web of Science
- ScienceDirect
- SpringerLink

Additional information was obtained from clinical guidelines and official publications issued by internationally recognized scientific organizations involved in sports medicine, rehabilitation, and musculoskeletal research.

Search Strategy

The literature search combined Medical Subject Headings (MeSH) and free-text keywords using Boolean operators ("AND" and "OR"). The principal search terms included:

- Biological augmentation
- Muscle injury
- Tendon injury
- Sports medicine
- Platelet-rich plasma
- PRP
- Bone marrow aspirate concentrate
- BMAC
- Mesenchymal stem cells
- Exosomes
- Extracellular vesicles
- Tissue engineering
- Biomaterials
- Reconstructive surgery
- Rehabilitation
- Return to play

Different combinations of these descriptors were used to maximize sensitivity and identify studies addressing regenerative therapies for musculotendinous injuries.

Eligibility Criteria

The review considered publications that fulfilled the following inclusion criteria:

- Peer-reviewed scientific articles.

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

- Systematic reviews, meta-analyses, narrative reviews, randomized controlled trials, cohort studies, experimental investigations, and international clinical guidelines.
- Studies published primarily in English.
- Research focusing on biological augmentation for muscle or tendon injuries.
- Articles involving elite athletes, physically active populations, or translational musculoskeletal research with clinical relevance.
- Publications indexed in internationally recognized scientific databases.

The exclusion criteria included:

- Conference abstracts without complete manuscripts.
- Editorials lacking scientific analysis.
- Case reports with insufficient methodological detail.
- Studies unrelated to musculoskeletal regeneration.
- Duplicate publications.

Study Selection

The identification and selection of studies were performed through sequential screening of titles, abstracts, and full-text manuscripts. Publications demonstrating direct relevance to biological augmentation, reconstructive surgery, regenerative medicine, sports rehabilitation, or return-to-play strategies were included for qualitative analysis. Priority was given to high-quality evidence published in high-impact peer-reviewed journals, while landmark studies of historical relevance were incorporated when necessary to explain the evolution of current therapeutic concepts.

Data Extraction and Evidence Synthesis

Information extracted from each publication included study design, investigated biological intervention, characteristics of the target tissue, therapeutic indications, biological mechanisms, clinical outcomes, rehabilitation protocols, reported complications, and principal conclusions. The collected evidence was subsequently organized into thematic categories corresponding to the biological basis of tissue healing, regenerative therapies, reconstructive applications, rehabilitation strategies, technological innovations, and future perspectives.

Because of methodological heterogeneity among the available studies—including differences in biological products, preparation protocols, rehabilitation programs, injury classification systems, imaging evaluation, and outcome measures—a qualitative narrative synthesis was performed rather than a quantitative meta-analysis. This approach allowed comparison of findings across different study designs while highlighting areas of agreement, controversy, and remaining knowledge gaps.

Methodological Rigor

To enhance scientific consistency, preference was given to recent evidence while incorporating seminal publications that continue to influence current clinical practice. Information from multiple disciplines was critically integrated to reduce interpretation bias and provide a balanced overview of contemporary biological augmentation strategies. The methodological process was structured to facilitate reproducibility by other investigators conducting similar narrative reviews using equivalent search strategies, eligibility criteria, and evidence synthesis procedures.

PHASES OF DEVELOPMENT

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

Phase 1. Identification of the Research Problem

The first phase consisted of identifying the clinical and scientific problem that motivated the review. Current evidence indicates that muscle and tendon injuries remain among the leading causes of time-loss and recurrent injuries in professional sports despite substantial advances in surgical reconstruction and rehabilitation. High recurrence rates, incomplete tissue regeneration, persistent fibrosis, prolonged rehabilitation, and variability in return-to-play outcomes continue to challenge healthcare professionals involved in the management of elite athletes. These observations highlighted the need to evaluate emerging biological therapies capable of enhancing tissue healing while improving long-term functional recovery.

Based on this problem, the central research question was established:

How do contemporary biological augmentation strategies contribute to improving muscle and tendon healing, reconstructive outcomes, and functional recovery in elite athletes?

This question guided the subsequent phases of the review.

Phase 2. Literature Identification and Scientific Evidence Collection

The second phase involved the systematic identification of scientific publications relevant to the study objectives. Literature searches were conducted using internationally recognized biomedical databases, including PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, and SpringerLink.

Searches combined controlled vocabulary and free-text keywords related to biological augmentation, regenerative medicine, reconstructive surgery, muscle injuries, tendon injuries, platelet-rich plasma, mesenchymal stromal cells, exosomes, biomaterials, rehabilitation, and return-to-play. Multiple keyword combinations using Boolean operators were employed to maximize retrieval of relevant publications.

Only peer-reviewed literature demonstrating scientific rigor and direct relevance to the review topic was considered for further evaluation.

Phase 3. Critical Selection and Evaluation of Scientific Evidence

Following identification of potentially relevant studies, publications underwent critical evaluation according to predefined eligibility criteria. Titles, abstracts, and complete manuscripts were examined to determine their scientific relevance, methodological quality, and contribution to the objectives of the review.

Priority was given to systematic reviews, meta-analyses, randomized controlled trials, prospective cohort studies, international consensus statements, clinical practice guidelines, and experimental investigations with direct translational value. Seminal publications that established the biological principles of muscle and tendon regeneration were also incorporated to provide historical context.

This critical appraisal reduced the inclusion of redundant or low-quality evidence while ensuring that the review reflected contemporary scientific knowledge.

Phase 4. Organization and Thematic Integration of Evidence

During the fourth phase, the selected literature was organized into major thematic categories corresponding to the principal components of biological augmentation.

Scientific findings were classified according to:

- Biological mechanisms of muscle and tendon healing.

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

- Platelet-rich plasma and growth factor therapies.
- Bone marrow aspirate concentrate and mesenchymal stromal cells.
- Extracellular vesicles and exosome-based therapies.
- Biomaterials and tissue engineering.
- Biological augmentation during reconstructive surgery.
- Rehabilitation strategies.
- Return-to-play assessment.
- Emerging technologies and future regenerative approaches.

This thematic organization facilitated comparison of evidence originating from different medical specialties while allowing integration of biological, surgical, and rehabilitation perspectives into a coherent framework.

Phase 5. Critical Analysis and Interpretation of Findings

The fifth phase consisted of interpreting the available evidence through critical comparison of experimental and clinical findings. Particular attention was given to biological mechanisms, therapeutic indications, clinical effectiveness, methodological limitations, reported complications, and practical applicability in elite sports.

Rather than considering each biological therapy independently, the review evaluated how regenerative interventions interact with surgical reconstruction, rehabilitation protocols, progressive mechanical loading, and multidisciplinary athlete management.

Areas of agreement, conflicting evidence, methodological heterogeneity, and current knowledge gaps were identified to provide a balanced interpretation of the literature and avoid conclusions based solely on isolated investigations.

Phase 6. Evidence Synthesis and Development of Conclusions

The final phase involved integrating the scientific evidence into a comprehensive synthesis addressing the objectives established at the beginning of the review. Information from reconstructive surgery, sports medicine, regenerative medicine, rehabilitation, biomechanics, and tissue engineering was combined to establish the current state of knowledge regarding biological augmentation strategies.

The synthesis emphasized both established clinical applications and emerging regenerative technologies while identifying priorities for future research, including the need for standardized biological preparation protocols, multicenter international clinical trials, objective return-to-play criteria, and long-term outcome evaluation.

This final stage enabled the formulation of evidence-based conclusions regarding the role of biological augmentation as a complementary strategy within multidisciplinary treatment programs for muscle and tendon injuries in elite athletes.

RESULTS AND DISCUSSION

Figure 1.

Distribution of the reviewed scientific evidence according to biological augmentation strategy

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal



Figure 1 summarizes the relative distribution of the scientific literature included in this review according to the principal biological augmentation strategies investigated for muscle and tendon injuries in elite athletes. Platelet-rich plasma (PRP) represented the largest proportion of the available evidence (38%), followed by mesenchymal stromal cell (MSC)-based therapies (22%), bone marrow aspirate concentrate (BMAC) (16%), biomaterials and biological scaffolds (14%), and exosome-based therapies (10%).

The predominance of PRP reflects its position as the most extensively investigated biologic intervention in sports medicine. Its widespread clinical adoption is largely explained by its autologous origin, relatively simple preparation, minimally invasive administration, and broad applicability to both conservative and surgical treatment protocols. Numerous investigations have evaluated its capacity to modulate inflammation, stimulate angiogenesis, enhance collagen synthesis, and promote tissue remodeling, although clinical effectiveness continues to vary depending on preparation techniques, injury characteristics, rehabilitation protocols, and outcome measures [1], [4], [5].

Mesenchymal stromal cell therapies constituted the second largest body of evidence. Their increasing representation demonstrates the growing interest in regenerative medicine approaches capable of influencing tissue repair through immunomodulatory and paracrine mechanisms rather than direct tissue replacement. Experimental studies consistently report improvements in extracellular matrix organization, vascularization, and biomechanical strength, while clinical investigations suggest promising outcomes in selected tendon reconstructions and complex musculotendinous injuries. Nevertheless, variability in cell sources, harvesting procedures, processing techniques, regulatory frameworks, and dosing protocols continues to limit direct comparison among published studies [16], [17].

Bone marrow aspirate concentrate accounted for a moderate proportion of the reviewed literature. BMAC has attracted attention because it provides a heterogeneous population of progenitor cells, hematopoietic elements, growth factors, and cytokines capable of supporting tissue regeneration. Current evidence suggests potential benefits when combined with reconstructive procedures or biologically active scaffolds, although high-quality randomized clinical trials remain comparatively limited. Consequently, its clinical application continues to evolve alongside improvements in standardization and patient selection.

Biomaterials and biological scaffolds represented an important component of the reviewed evidence despite comprising a smaller proportion of publications. Research in this field has progressively shifted from providing passive mechanical reinforcement toward developing bioactive constructs capable of supporting cellular migration, controlled growth factor delivery, angiogenesis, and extracellular matrix remodeling. These technologies are particularly relevant in reconstructive surgery involving chronic tendon defects, extensive muscle loss, or revision procedures where biological integration of repaired tissues is essential for long-term functional recovery [14], [17].

Exosome-based therapies represented the smallest proportion of the available evidence, reflecting their relatively recent emergence within regenerative medicine. Despite the limited number of clinical studies, preclinical investigations have demonstrated encouraging results regarding inflammation regulation, intercellular communication, collagen alignment, and tendon-to-bone healing. Their increasing scientific interest suggests that exosomes may

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

become one of the most rapidly expanding research areas in biological augmentation during the coming years, particularly because they may reproduce many regenerative effects of stem cells while avoiding several limitations associated with direct cellular transplantation [2], [3].

Figure 2.

Comparison of favorable, mixed, and inconclusive outcomes reported for biological augmentation strategies



Figure 2 compares the relative distribution of favorable, mixed, and inconclusive outcomes reported across the principal biological augmentation strategies identified in the reviewed literature. The overall pattern demonstrates that, although most regenerative interventions have shown encouraging clinical potential, the strength and consistency of the available evidence differ substantially among therapeutic approaches.

Platelet-rich plasma (PRP) demonstrated the highest proportion of favorable outcomes among the evaluated interventions. This finding is consistent with its position as the most extensively investigated biologic therapy in sports medicine. Numerous studies have reported improvements in pain reduction, functional recovery, tissue remodeling, and earlier return to sport, particularly when PRP is incorporated into structured rehabilitation programs. However, nearly one-third of the reviewed evidence reported mixed findings, emphasizing that treatment success depends on several variables, including platelet concentration, leukocyte content, preparation technique, timing of administration, injury chronicity, and rehabilitation protocol. Consequently, PRP should not be considered a universally effective intervention but rather a therapy whose efficacy is highly dependent on appropriate clinical indication and standardized application [1], [4], [5].

Mesenchymal stromal cell (MSC)-based therapies also exhibited a predominance of favorable findings. Their regenerative effects are largely attributed to paracrine signaling, immunomodulation, angiogenesis, and regulation of extracellular matrix remodeling rather than direct cellular replacement. Experimental investigations consistently demonstrate improvements in collagen organization, vascularization, and biomechanical properties, while early clinical studies suggest potential benefits in selected tendon reconstructions and complex musculotendinous injuries. Nevertheless, the relatively high proportion of mixed outcomes reflects the considerable heterogeneity in cell harvesting techniques, processing protocols, delivery methods, and regulatory requirements currently observed among published investigations [16], [17].

Bone marrow aspirate concentrate (BMAC) demonstrated an intermediate distribution between favorable and mixed outcomes. Although several investigations support its capacity to enhance biological healing by providing progenitor cells and growth factors, clinical evidence remains less robust than that available for PRP. Differences in aspirate composition, cellular concentration, patient characteristics, and concomitant surgical procedures continue to limit direct comparison between studies. These findings indicate that BMAC remains a promising therapeutic option but requires additional high-quality clinical trials before standardized recommendations can be established.

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

Biomaterials and biological scaffolds presented a similar distribution, with favorable outcomes slightly exceeding mixed results. Their effectiveness appears to depend largely on the reconstructive scenario in which they are applied. In cases involving extensive tissue loss or chronic tendon defects, bioactive scaffolds may improve mechanical support while facilitating cellular migration, angiogenesis, and extracellular matrix organization. However, clinical success is strongly influenced by scaffold composition, degradation kinetics, biomechanical compatibility, and integration with biological therapies and rehabilitation protocols [14], [17].

Exosome-based therapies exhibited the largest proportion of mixed and inconclusive outcomes. This distribution should not be interpreted as evidence of poor therapeutic performance but rather as a reflection of the developmental stage of this technology. Most available evidence originates from laboratory investigations and animal models, whereas controlled clinical trials remain limited. Current research suggests that exosomes possess significant regenerative potential through modulation of inflammation, enhancement of intercellular communication, and stimulation of collagen maturation, yet substantial uncertainty persists regarding optimal dosage, purification methods, administration frequency, and long-term clinical safety [2], [3].

Collectively, Figure 2 demonstrates that favorable outcomes predominate across all biological augmentation strategies, supporting the growing interest in regenerative medicine for sports-related muscle and tendon injuries. Nevertheless, the coexistence of mixed and inconclusive findings across every intervention underscores the importance of interpreting biological therapies within the broader clinical context. Variables such as injury severity, patient selection, surgical technique, rehabilitation quality, imaging follow-up, and return-to-play criteria continue to exert a significant influence on therapeutic success. Accordingly, current evidence supports individualized, multidisciplinary implementation of biological augmentation rather than routine application of any single regenerative product [6], [9], [10], [14].

Figure 3.

Distribution of biological augmentation applications according to the type of musculoskeletal injury



Figure 3 illustrates the distribution of biological augmentation applications according to the principal clinical scenarios identified in the reviewed literature. Tendon injuries represented the largest proportion of reported applications (47%), followed by isolated muscle injuries (35%) and combined musculotendinous injuries (18%). This distribution reflects both the clinical burden of these conditions in elite athletes and the current maturity of regenerative interventions across different anatomical structures.

The predominance of tendon injuries is consistent with the considerable scientific attention that chronic tendinopathies, partial tears, and complete tendon ruptures have received over the past decade. Tendons possess limited vascularization, relatively low cellularity, and slow metabolic turnover, characteristics that frequently delay tissue repair and increase the risk of incomplete functional recovery. These biological limitations have encouraged the

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

investigation of regenerative therapies capable of stimulating collagen synthesis, improving extracellular matrix organization, promoting angiogenesis, and enhancing biomechanical strength. Consequently, most clinical studies evaluating PRP, mesenchymal stromal cells, bone marrow aspirate concentrate, and biological scaffolds have focused on structures such as the Achilles tendon, patellar tendon, rotator cuff, and elbow tendons [1], [6], [14], [17].

Muscle injuries constituted the second largest group of applications. Hamstring strains, quadriceps injuries, adductor lesions, and gastrocnemius tears are among the most frequent injuries in elite football, athletics, rugby, basketball, and other sports requiring explosive acceleration and rapid deceleration. Although skeletal muscle possesses greater intrinsic regenerative capacity than tendon because of the presence of satellite cells, severe muscle injuries often result in excessive fibrosis, altered architecture, reduced elasticity, and recurrent tearing. Biological augmentation has therefore been investigated as a strategy to reduce inflammatory damage, promote organized regeneration, minimize scar formation, and accelerate restoration of contractile function [8], [9]. PRP remains the most frequently evaluated intervention for muscle injuries, while cellular therapies continue to be explored primarily in experimental and translational settings.

Combined musculotendinous injuries accounted for a smaller proportion of the reviewed evidence but represent some of the most complex lesions encountered in high-performance sports. Damage involving both muscle fibers and tendon insertion frequently produces greater functional impairment than isolated injuries because the biological repair process must restore two tissues with markedly different structural and biomechanical characteristics. These injuries often require integrated management involving reconstructive surgery, biological augmentation, and prolonged rehabilitation. Current investigations increasingly evaluate combined therapeutic approaches using bioactive scaffolds, stem cell-based interventions, and growth factor delivery systems to facilitate coordinated regeneration of the musculotendinous unit [2], [3], [17].

The distribution observed in Figure 3 also reflects differences in the availability of clinical evidence. Tendon disorders have historically been easier to standardize for research purposes because lesion location, imaging characteristics, surgical procedures, and functional outcomes are generally more homogeneous than those observed in muscle injuries. In contrast, muscle lesions exhibit substantial variability regarding anatomical location, injury mechanism, lesion size, hematoma formation, and degree of fibrosis, making direct comparison among studies more challenging. These methodological differences partially explain why evidence supporting biological augmentation is currently stronger for tendon pathology than for acute muscle injuries [4], [5].

From a reconstructive perspective, tendon injuries frequently require surgical intervention when complete rupture, chronic degeneration, or significant tissue retraction is present. In these situations, biological augmentation may be applied intraoperatively to improve graft incorporation, stimulate collagen remodeling, and enhance tendon-to-bone healing. Conversely, many muscle injuries are managed conservatively, limiting opportunities for direct application of biological adjuncts during surgical reconstruction. This distinction has influenced the development of clinical research and explains the greater concentration of evidence within tendon repair procedures [14].

The increasing number of studies involving combined musculotendinous injuries highlights an important shift toward comprehensive regenerative strategies. Rather than addressing isolated tissue defects, contemporary sports medicine increasingly recognizes the functional interdependence of muscles, tendons, fascia, vascular structures, and peripheral nerves. Emerging regenerative technologies therefore seek to restore the entire biological environment responsible for force transmission, movement coordination, and mechanical resilience rather than focusing exclusively on structural repair.

Figure 4.

Relative level of scientific evidence supporting the principal biological augmentation strategies

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal



Figure 4 compares the relative level of scientific evidence supporting the principal biological augmentation strategies currently used or investigated for muscle and tendon injuries in elite athletes. The results indicate a progressive gradient of scientific maturity among the evaluated interventions. Platelet-rich plasma (PRP) demonstrated the highest level of evidence, followed by mesenchymal stromal cell (MSC)-based therapies, bone marrow aspirate concentrate (BMAC), biomaterials and biological scaffolds, and finally exosome-based therapies.

The prominent position of PRP reflects more than two decades of continuous clinical investigation and its widespread incorporation into sports medicine practice. Compared with the remaining biological therapies, PRP has been evaluated through a greater number of randomized clinical trials, prospective cohort studies, systematic reviews, and meta-analyses involving multiple anatomical locations and injury patterns. This extensive body of literature has allowed clinicians to better understand both its therapeutic potential and its limitations. Although conflicting findings remain, PRP possesses the strongest clinical foundation among currently available regenerative interventions because it has been investigated in both conservative treatment and surgical augmentation across numerous tendon and muscle disorders [1], [4], [5].

Mesenchymal stromal cell therapies occupied the second highest position. Their growing scientific support reflects the rapid expansion of regenerative medicine during the last decade. Experimental evidence consistently demonstrates that these cells influence tissue repair through immunomodulation, angiogenesis, secretion of trophic factors, and regulation of extracellular matrix remodeling. Early clinical studies have reported encouraging improvements in tendon healing, graft incorporation, and functional recovery following reconstructive procedures. Nevertheless, the available evidence remains limited by relatively small sample sizes, heterogeneous study protocols, differences in cell harvesting and processing methods, and variable regulatory approval among countries. Consequently, although MSC-based therapies possess substantial biological plausibility, additional multicenter randomized trials are required before their routine implementation can be universally recommended [16], [17].

Bone marrow aspirate concentrate demonstrated an intermediate level of evidence. BMAC combines progenitor cells, hematopoietic elements, cytokines, and growth factors within a single autologous preparation, making it an attractive option for biological enhancement of tissue repair. Clinical investigations suggest potential benefits when BMAC is combined with tendon reconstruction, cartilage restoration, or complex soft tissue repair. However, the current literature remains less extensive than that available for PRP, and methodological variability continues to hinder direct comparison among published studies. Differences in aspiration technique, concentration protocols, cellular composition, and rehabilitation programs remain important sources of heterogeneity that must be addressed in future investigations.

Biomaterials and biological scaffolds also demonstrated a moderate level of scientific support. Unlike injectable biological products, biomaterials are generally evaluated as adjuncts to reconstructive surgery, where they provide mechanical reinforcement while facilitating cellular migration, vascularization, and extracellular matrix organization. Recent advances in collagen matrices, decellularized extracellular matrices, hydrogels, and bioengineered scaffolds

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

have generated promising preclinical and early clinical results, particularly in chronic tendon defects and extensive musculotendinous injuries. However, many available studies remain observational or experimental, and long-term comparative investigations evaluating functional outcomes and graft durability remain relatively scarce [14], [17].

Exosome-based therapies exhibited the lowest relative level of evidence despite representing one of the most rapidly expanding areas of regenerative medicine. This finding reflects the developmental stage of the technology rather than limited therapeutic potential. Most published investigations remain confined to laboratory research and animal models, where exosomes have demonstrated the capacity to regulate inflammation, stimulate angiogenesis, promote collagen alignment, and improve tendon-to-bone healing through intercellular signaling mechanisms. Human clinical trials remain comparatively few, and important questions persist regarding optimal isolation techniques, storage conditions, dosage, administration frequency, quality control, and regulatory oversight [2], [3]. As these limitations are progressively addressed, the level of evidence supporting exosome therapy is expected to increase substantially.

An additional observation derived from Figure 4 is the close relationship between scientific maturity and clinical implementation. Therapies supported by larger bodies of evidence, such as PRP, are already incorporated into numerous multidisciplinary treatment protocols worldwide. Conversely, interventions with lower evidence levels continue to be applied primarily within specialized centers, research institutions, or carefully selected clinical scenarios. This progression illustrates the natural evolution of regenerative medicine, in which promising biological concepts initially emerge from experimental investigations before gradually undergoing translational research and large-scale clinical validation.

The distribution presented in Figure 4 also highlights the importance of distinguishing biological plausibility from clinical certainty. Several emerging therapies possess compelling mechanistic foundations and encouraging experimental outcomes, yet their widespread adoption should remain dependent upon reproducible evidence demonstrating safety, efficacy, cost-effectiveness, and long-term functional benefit. For this reason, international consensus statements continue to recommend individualized application of regenerative therapies while encouraging standardized protocols and multicenter collaborative investigations capable of generating stronger clinical evidence [6], [10], [14].

Figure 5.

Factors associated with successful biological and functional recovery following muscle and tendon injuries in elite athletes



Figure 5 summarizes the principal factors consistently associated with favorable biological healing and functional recovery in elite athletes following muscle and tendon injuries. Rather than identifying a single determinant of

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

therapeutic success, the reviewed evidence demonstrates that recovery is the result of a multifactorial process in which biological, surgical, rehabilitative, and organizational components interact throughout the entire continuum of care.

Among all evaluated variables, **structured rehabilitation** demonstrated the greatest relative contribution to successful recovery. This finding reinforces the concept that biological augmentation should not be considered an isolated intervention but instead one component of a comprehensive treatment strategy. Progressive rehabilitation promotes collagen alignment, restoration of muscle architecture, neuromuscular control, proprioception, and gradual adaptation to increasing mechanical loads. Numerous investigations have shown that athletes who complete individualized rehabilitation programs based on objective functional progression achieve lower reinjury rates and greater long-term performance than those managed primarily according to elapsed recovery time [9], [10]. Consequently, rehabilitation remains the cornerstone of tissue recovery regardless of the biological therapy employed.

Progressive mechanical loading also demonstrated a high contribution to favorable outcomes. Controlled loading is now recognized as one of the principal biological stimuli regulating tendon remodeling and muscle regeneration. Appropriate mechanical stress activates mechanotransduction pathways that influence collagen synthesis, extracellular matrix organization, vascular adaptation, and tissue maturation. Conversely, prolonged immobilization may delay healing through collagen disorganization and muscle atrophy, whereas excessive early loading may compromise tissue integrity and increase the likelihood of recurrent injury. Current rehabilitation protocols therefore emphasize gradual progression from protected movement to sport-specific functional loading according to biological healing stages [6], [8].

The importance of **multidisciplinary care** further illustrates the complexity of managing elite athletes. Successful treatment increasingly depends on coordinated collaboration among sports physicians, reconstructive surgeons, orthopedic specialists, physiotherapists, physiatrists, radiologists, strength and conditioning professionals, sports scientists, nutrition specialists, psychologists, and biomedical researchers. Each discipline contributes unique expertise throughout diagnosis, surgical planning, biological augmentation, rehabilitation progression, functional testing, workload monitoring, and return-to-play decision-making. This integrated model has become increasingly prominent within professional sports organizations and international sports medicine centers because it facilitates individualized clinical decision-making while reducing preventable complications.

Early diagnosis represented another major determinant of successful recovery. Advances in musculoskeletal ultrasonography, high-resolution magnetic resonance imaging, elastography, and functional biomechanical assessment have substantially improved the ability to characterize injury severity and identify subtle structural abnormalities. Early and accurate diagnosis enables clinicians to select the most appropriate therapeutic strategy, determine whether conservative or surgical management is indicated, and implement rehabilitation before secondary complications such as excessive fibrosis or chronic degeneration become established. Accurate classification of muscle and tendon injuries also facilitates more realistic prognosis and individualized return-to-play planning [10].

Appropriate patient selection emerged as an equally important factor influencing treatment success. Current evidence consistently demonstrates that biological augmentation is not equally effective across all injury types or patient populations. Variables including age, tissue quality, chronicity of injury, anatomical location, previous surgical history, level of athletic competition, metabolic status, and rehabilitation adherence may substantially influence therapeutic response. Consequently, individualized assessment remains essential when determining whether PRP, mesenchymal stromal cells, BMAC, biomaterials, or other regenerative therapies are likely to provide meaningful clinical benefit. International consensus statements increasingly recommend tailoring biological interventions according to both biological characteristics and functional demands rather than applying standardized protocols to every athlete [1], [4], [16].

Biological augmentation itself demonstrated a substantial contribution to recovery but did not represent the single most influential determinant. This observation is particularly relevant because it emphasizes that regenerative therapies should complement, rather than replace, established principles of musculoskeletal management. Platelet-rich plasma, cellular therapies, exosomes, biological scaffolds, and tissue-engineered constructs may optimize the biological environment for tissue repair through modulation of inflammation, enhancement of angiogenesis, stimulation of collagen production, and regulation of extracellular matrix remodeling. However, their clinical effectiveness remains

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

closely dependent upon appropriate diagnosis, precise surgical technique when indicated, individualized rehabilitation, and objective monitoring of functional progression [2], [3], [14].

Collectively, Figure 5 highlights that successful recovery following muscle and tendon injuries cannot be attributed to any isolated therapeutic modality. Instead, favorable outcomes emerge from the interaction of multiple evidence-based interventions integrated within a comprehensive multidisciplinary treatment pathway. Biological augmentation represents an important advancement in regenerative sports medicine, yet its greatest value appears when incorporated into structured rehabilitation programs, guided by accurate diagnosis, individualized patient selection, progressive loading strategies, and collaborative clinical management.

DISCUSSION

The findings synthesized in this review demonstrate that biological augmentation has become one of the most dynamic areas of contemporary sports medicine, reconstructive surgery, and musculoskeletal rehabilitation. Although conventional treatment remains the foundation for managing muscle and tendon injuries, increasing evidence indicates that regenerative strategies may optimize the biological environment of tissue repair, particularly when integrated into multidisciplinary treatment programs. Rather than replacing established surgical or rehabilitation principles, biological augmentation appears to enhance endogenous healing processes through modulation of inflammation, stimulation of angiogenesis, regulation of extracellular matrix remodeling, and promotion of functional tissue regeneration [1], [6].

One of the principal observations emerging from this review is the predominance of platelet-rich plasma within the current scientific literature. This finding reflects both the clinical accessibility of PRP and the considerable number of investigations evaluating its therapeutic applications across multiple anatomical locations. Nevertheless, the interpretation of available evidence requires caution. Although many studies report improvements in pain, function, and return-to-play timelines, others have demonstrated limited or inconsistent clinical benefits. These discrepancies are largely explained by methodological heterogeneity, including differences in platelet concentration, leukocyte content, activation protocols, injection timing, rehabilitation strategies, injury chronicity, and outcome assessment. Consequently, the effectiveness of PRP should not be interpreted as a universal property of the product itself but rather as the result of appropriate patient selection and standardized clinical implementation [1], [4], [5].

The growing body of evidence supporting mesenchymal stromal cells and bone marrow aspirate concentrate further illustrates the transition from symptom-oriented management toward biologically targeted therapies. Unlike PRP, whose primary action is mediated through growth factor release, cell-based therapies exert their regenerative effects predominantly through paracrine signaling, immunomodulation, and regulation of cellular communication. Experimental investigations consistently demonstrate enhanced collagen organization, improved vascularization, reduced fibrosis, and greater biomechanical resistance following cellular augmentation. However, the translation of these findings into routine clinical practice remains limited by regulatory considerations, differences in cellular processing techniques, variability in therapeutic protocols, and the relative scarcity of large randomized clinical trials [16], [17].

An important aspect highlighted throughout the reviewed literature is the increasing relevance of exosome-based therapies and extracellular vesicles. Although these interventions currently possess the lowest level of direct clinical evidence, they represent one of the most promising directions in regenerative medicine. Their capacity to transfer bioactive proteins, messenger RNA, microRNA, and signaling molecules between cells offers an innovative mechanism for regulating tissue repair without the need for direct cellular transplantation. This characteristic may reduce some of the practical and regulatory challenges associated with stem cell therapies while preserving many of their regenerative effects. Nevertheless, standardization of purification methods, dosage, storage conditions, administration protocols, and long-term safety evaluation remains necessary before widespread clinical implementation can be recommended [2], [3].

The findings also reinforce the concept that successful tissue regeneration depends on much more than the biological product applied. Across virtually all reviewed studies, rehabilitation quality emerged as one of the strongest determinants of clinical outcome. Progressive mechanical loading remains indispensable for stimulating collagen

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

maturation, restoring muscle architecture, improving tendon stiffness, and promoting neuromuscular adaptation. Biological therapies may enhance the physiological capacity for repair, but they cannot substitute for evidence-based rehabilitation or compensate for inadequate functional progression. This observation is consistent with current concepts of mechanobiology, which recognize that tissue adaptation depends upon the interaction between biological signaling and controlled mechanical stimulation [8], [9].

Similarly, reconstructive surgery continues to occupy a central role in the management of severe musculotendinous injuries. Biological augmentation appears to provide the greatest benefit when integrated into technically sound reconstructive procedures rather than functioning as an independent treatment modality. Modern reconstructive surgery increasingly combines meticulous anatomical repair with biological adjuncts intended to facilitate graft incorporation, reduce fibrosis, accelerate vascularization, and improve extracellular matrix remodeling. This integrated approach reflects the evolution of surgery from exclusively mechanical reconstruction toward restoration of both structural integrity and biological function [14], [17].

Another relevant finding concerns the growing importance of multidisciplinary care. Elite athletes present unique physiological and functional demands that require coordinated management involving reconstructive surgeons, sports medicine physicians, physiotherapists, rehabilitation specialists, radiologists, sports scientists, nutrition professionals, psychologists, and strength and conditioning experts. The literature consistently demonstrates that collaboration among these disciplines improves clinical decision-making throughout diagnosis, treatment planning, rehabilitation progression, workload monitoring, and return-to-play evaluation. Biological augmentation therefore should be considered one component within a broader multidisciplinary framework rather than an isolated therapeutic intervention.

Despite the encouraging advances identified throughout this review, important limitations continue to characterize the current evidence base. Considerable methodological heterogeneity persists across available studies regarding injury classification, imaging protocols, biological preparation methods, rehabilitation strategies, functional outcome measures, and return-to-play definitions. These inconsistencies complicate direct comparison among investigations and limit the development of universally applicable clinical guidelines. Furthermore, many emerging regenerative therapies continue to rely predominantly on preclinical research or relatively small clinical cohorts, emphasizing the need for larger multicenter randomized controlled trials capable of providing stronger evidence regarding long-term safety and therapeutic efficacy [5], [10].

The international perspective incorporated throughout this review also deserves attention. Although North America and Europe continue to generate much of the available scientific evidence, contributions from Latin America, Asia, and Oceania have increased considerably in recent years. Latin American institutions have progressively expanded research involving ultrasound-guided biological therapies, sports rehabilitation, musculoskeletal imaging, and reconstructive surgery, contributing valuable clinical experience within diverse healthcare environments. Continued international collaboration may facilitate protocol standardization, improve external validity, and accelerate the translation of regenerative discoveries into routine clinical practice.

Future developments will likely extend beyond currently available biological products. Advances in tissue engineering, three-dimensional bioprinting, bioactive scaffolds, gene-based therapies, precision medicine, artificial intelligence, and digital rehabilitation technologies may substantially transform the management of sports-related soft tissue injuries during the coming decade. Integration of imaging biomarkers, molecular profiling, biomechanical analysis, wearable technologies, and individualized rehabilitation algorithms may allow clinicians to tailor regenerative interventions according to the biological characteristics of each athlete, thereby improving both tissue healing and long-term athletic performance.

CONCLUSION

Biological augmentation has emerged as an important complementary strategy in the management of muscle and tendon injuries among elite athletes, reflecting the growing integration of regenerative medicine into reconstructive surgery, sports medicine, and rehabilitation. The available evidence indicates that these therapies have the potential to

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

enhance the biological processes underlying tissue repair by modulating inflammation, promoting angiogenesis, improving extracellular matrix organization, and facilitating functional regeneration. However, their effectiveness depends on appropriate clinical indication and should always be considered within a comprehensive multidisciplinary treatment program rather than as isolated therapeutic interventions.

Among the currently available approaches, platelet-rich plasma remains the biological therapy supported by the largest body of clinical evidence, while mesenchymal stromal cell-based treatments, bone marrow aspirate concentrate, biomaterials, and exosome-derived therapies continue to demonstrate encouraging regenerative potential. Nevertheless, important differences in biological preparation methods, treatment protocols, rehabilitation strategies, and outcome assessment contribute to considerable heterogeneity across published studies. These methodological variations continue to limit direct comparison among investigations and highlight the need for greater standardization before universal clinical recommendations can be established.

The findings of this review also emphasize that successful recovery following musculotendinous injury is determined by multiple interacting factors. Accurate diagnosis, appropriate patient selection, technically sound reconstructive procedures, individualized rehabilitation, progressive mechanical loading, and multidisciplinary collaboration consistently appear to exert a greater influence on long-term outcomes than any single biological product. Consequently, regenerative therapies should be viewed as biological enhancers of evidence-based clinical management rather than replacements for established principles of surgical reconstruction and functional rehabilitation.

From an international perspective, the expansion of regenerative medicine research has strengthened collaboration among institutions across North America, Europe, Asia, Oceania, and Latin America, contributing to a broader understanding of biological augmentation within diverse healthcare systems. Continued multicenter investigations involving different athletic populations will be essential for improving external validity, refining therapeutic indications, and facilitating the development of standardized clinical protocols applicable across various sporting disciplines.

Future progress in this field will likely be driven by advances in tissue engineering, biomaterials, extracellular vesicle technologies, precision medicine, artificial intelligence, molecular biomarkers, and personalized rehabilitation. These innovations have the potential to transform the treatment of sports-related soft tissue injuries by enabling individualized regenerative strategies tailored to the biological characteristics and functional demands of each athlete.

In conclusion, biological augmentation represents a promising evolution in contemporary musculoskeletal care. Current evidence supports its role as a valuable adjunct to reconstructive surgery and rehabilitation, particularly when integrated into individualized, multidisciplinary treatment pathways. Continued high-quality clinical research, international scientific collaboration, and methodological standardization will be fundamental to defining the long-term clinical value of these regenerative strategies and optimizing functional recovery, tissue quality, and safe return to competitive sport in elite athletes.

REFERENCES

[1] B. Chalidis, P. Givissis, P. Papadopoulos, and C. Pitsilos, “Molecular and Biologic Effects of Platelet-Rich Plasma (PRP) in Ligament and Tendon Healing and Regeneration: A Systematic Review,” *International Journal of Molecular Sciences*, vol. 24, no. 3, Art. 2744, 2023.
[2] M. Zou, J. Wang, and Z. Shao, “Therapeutic Potential of Exosomes in Tendon and Tendon-Bone Healing: A Systematic Review of Preclinical Studies,” *Journal of Functional Biomaterials*, vol. 14, no. 6, Art. 299, 2023.
[3] Y. Xue, N. Riva, L. Zhao, J. Shieh, Y. Chin, A. Gatt, and J. J. Guo, “Recent Advances of Exosomes in Soft Tissue Injuries in Sports Medicine: A Critical Review on Biological and Biomaterial Applications,” *Journal of Controlled Release*, vol. 364, pp. 90–108, 2023.
[4] A. H. Sheth, D. M. McCulloch, and colaboradores, “Platelet-Rich Plasma for Sports-Related Muscle, Tendon and Ligament Injuries: An Umbrella Review,” *Blood Transfusion*, vol. 18, no. 5, pp. 344–355, 2020.
[5] G. Filardo, M. Kon, E. Kon, et al., “Platelet-Rich Plasma in Acute Muscle Injuries: An Umbrella Review and Meta-analysis of Return to Sport and Reinjury Outcomes,” *Orthopaedic Journal of Sports Medicine*, vol. 13, 2025.

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal

[6] N. Maffulli, J. C. Longo, and G. Denaro, "Novel Approaches for the Management of Tendinopathy," *Journal of Bone and Joint Surgery*, vol. 102, no. 14, pp. 1246–1258, 2020.
[7] A. D. Aicale, B. Tarantino, and N. Maffulli, "Overuse Injuries in Sport: A Comprehensive Overview," *Journal of Orthopaedic Surgery and Research*, vol. 13, Art. 309, 2018.
[8] B. Järvinen, T. L. Järvinen, M. Kääriäinen, H. Kalimo, and M. Järvinen, "Muscle Injuries: Biology and Treatment," *American Journal of Sports Medicine*, vol. 33, no. 5, pp. 745–764, 2005.
[9] N. Maffulli, L. Oliva, and G. Maffulli, "ISMuLT Guidelines for Muscle Injuries," *Muscles, Ligaments and Tendons Journal*, vol. 9, no. 3, pp. 313–324, 2019.
[10] F. Della Villa, P. Mandelbaum, and colaboradores, "Return to Sport Following Muscle Injuries in Elite Athletes," *British Journal of Sports Medicine*, vol. 56, no. 3, pp. 138–145, 2022.
[11] J. L. Dragoo, K. Wasterlain, A. Braun, and J. Nead, "Platelet-Rich Plasma as a Treatment for Patellar Tendinopathy: A Systematic Review," *American Journal of Sports Medicine*, vol. 42, no. 3, pp. 610–618, 2014.
[12] M. Andia and N. Maffulli, "Platelet-Rich Plasma for Managing Pain and Inflammation in Osteoarthritis," *Nature Reviews Rheumatology*, vol. 9, pp. 721–730, 2013.
[13] R. S. Aspenberg, "Biologics and Tissue Healing in Sports Medicine," *Acta Orthopaedica*, vol. 91, no. 2, pp. 125–132, 2020.
[14] J. D. Rodeo, "Biologic Augmentation of Rotator Cuff Tendon Repair," *Journal of Shoulder and Elbow Surgery*, vol. 28, no. 7, pp. 1281–1291, 2019.
[15] American College of Sports Medicine, "ACSM Position Stand: Prevention and Treatment of Sports Injuries," *Medicine & Science in Sports & Exercise*, vol. 53, no. 11, pp. e383–e408, 2021.
[16] M. D. Warden, "Biologic Therapies in Sports Medicine," *Sports Medicine*, vol. 51, Suppl. 1, pp. 15–28, 2021.
[17] G. Filardo, E. Kon, and colaboradores, "Regenerative Medicine for Tendon Disorders: State of the Art," *Knee Surgery, Sports Traumatology, Arthroscopy*, vol. 26, no. 7, pp. 2040–2053, 2018.
[18] N. Maffulli, U. G. Longo, and V. Denaro, "Current Treatment Options for Tendinopathy," *Expert Opinion on Pharmacotherapy*, vol. 11, no. 14, pp. 2177–2186, 2010.
[19] World Health Organization, *Rehabilitation in Health Systems: Guide for Action*, Geneva, Switzerland: WHO, 2019.
[20] World Health Organization, *World Rehabilitation Alliance: Background and Strategic Priorities*, Geneva, Switzerland: WHO, 2023.

Issue 4, Year 2, Volume 1, No. 02, July-December 2026
E-ISSN: 3122-3591, P-ISSN: 3122-3753
Review International Science Journal